The relationship between uric acid levels and Huntington's disease progression
Identifieur interne : 000343 ( Istex/Curation ); précédent : 000342; suivant : 000344The relationship between uric acid levels and Huntington's disease progression
Auteurs : Peggy Auinger [États-Unis] ; Karl Kieburtz [États-Unis] ; Michael Mcdermott [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-01-30.
English descriptors
- KwdEn :
Abstract
Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE‐HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22907
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000343
Links to Exploration step
ISTEX:600962A0251CB74FF3391D05035604C8104C4E44Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The relationship between uric acid levels and Huntington's disease progression</title><author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name><affiliation wicri:level="2"><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael" last="Mcdermott">Michael Mcdermott</name><affiliation wicri:level="2"><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester</wicri:cityArea></affiliation><affiliation wicri:level="2"><mods:affiliation>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:600962A0251CB74FF3391D05035604C8104C4E44</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22907</idno><idno type="url">https://api.istex.fr/document/600962A0251CB74FF3391D05035604C8104C4E44/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000343</idno><idno type="wicri:Area/Istex/Curation">000343</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The relationship between uric acid levels and Huntington's disease progression</title><author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name><affiliation wicri:level="2"><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael" last="Mcdermott">Michael Mcdermott</name><affiliation wicri:level="2"><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester</wicri:cityArea></affiliation><affiliation wicri:level="2"><mods:affiliation>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-30">2010-01-30</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="224">224</biblScope><biblScope unit="page" to="228">228</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">600962A0251CB74FF3391D05035604C8104C4E44</idno><idno type="DOI">10.1002/mds.22907</idno><idno type="ArticleID">MDS22907</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term><term>progression</term><term>uric acid</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE‐HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000343 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000343 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:600962A0251CB74FF3391D05035604C8104C4E44
|texte= The relationship between uric acid levels and Huntington's disease progression
}}
| This area was generated with Dilib version V0.6.19. |  |